R. Webster

发表

Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man

Maurice Dickins, Iain Gardner, Hannah M. Jones, 2008 .

Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.

Derek Leishman, D. Leishman, R. Webster, 2002, Current opinion in drug discovery & development.

PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals

P. Taupin, D. Walker, B. K. Park, 2009 .

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

David A. Price, A. Wood, P. Dorr, 2005, Antimicrobial Agents and Chemotherapy.

The discovery of long acting β2-adrenoreceptor agonists

Alan Daniel Brown, Mark E. Bunnage, M. Bunnage, 2007 .

Identification of HCV Inhibitors from a Cell-Based Sub-Genomic Replicon Screen

Stephen M. Shaw, D. Pryde, C. Pickford, 2013 .

Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog

D. Walker, D. Leishman, A. Harrison, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor XaI16L.

C. Parng, A. Joyce, B. Gorovits, 2017, Journal of pharmaceutical sciences.

Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.

Catherine Burt, Chris Phillips, T. Knöchel, 2009, Journal of medicinal chemistry.

PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies

J. Stadler, Dennis A. Smith, R. Webster, 2007, Drug Metabolism and Disposition.

Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C.

P. H. van der Graaf, P. Chan, H. Jones, 2012, British journal of clinical pharmacology.

Impact of Physicochemical and Structural Properties on the Pharmacokinetics of a Series of α1L-Adrenoceptor Antagonists

K. Beaumont, I. Gardner, P. Morgan, 2007, Drug Metabolism and Disposition.

Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man

D. Walker, S. Roffey, S. Cole, 2003, Xenobiotica; the fate of foreign compounds in biological systems.

Disposition of biologics.

R. Webster, K. Brady, 2012, Advances in pharmacology.

Evaluation of the role of the asialoglycoprotein receptor in the clearance of UK-279,276 (recombinant neutrophil inhibitory factor)

D. Walker, R. Hyland, R. Webster, 2003, Xenobiotica; the fate of foreign compounds in biological systems.

Quantitative biodistribution of biotherapeutics at whole body, organ and cellular levels by autoradiography.

Denise M O'Hara, Stephen Harris, A. Mcewen, 2018, Bioanalysis.

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

David A. Price, A. Wood, P. Dorr, 2005, Antimicrobial Agents and Chemotherapy.

Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.

P. Fish, S. Bailey, James E. J. Mills, 2008, Bioorganic & medicinal chemistry letters.

Pharmacokinetics and clearance processes of UK-279,276 (rNIF) in rat and dog: Comparison with human data

D. Walker, R. Webster, A. Edgington, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.

M. Bunnage, David A. Price, A. Brown, 2010, Journal of medicinal chemistry.

Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.

David A. Price, A. Wood, R. Corbau, 2009, Bioorganic & medicinal chemistry letters.

Comparison of the Non‐Nucleoside Reverse Transcriptase Inhibitor Lersivirine with its Pyrazole and Imidazole Isomers

Chris Phillips, R. Corbau, C. Mowbray, 2011, Chemical biology & drug design.

The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile—Part 1

Stephen M. Shaw, J. Chiva, Florian Wakenhut, 2014, ChemMedChem.

Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist.

K. Beaumont, I. Gardner, R. Webster, 2003, Current drug metabolism.

A Physiologically‐Based Pharmacokinetic Model for the Prediction of “Half‐Life Extension” and “Catch and Release” Monoclonal Antibody Pharmacokinetics

P. Jasper, J. Tolsma, Dean M. Messing, 2020, CPT: pharmacometrics & systems pharmacology.

A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.

G. Kay, P. Bungay, M. Michel, 2011, British journal of clinical pharmacology.

Discovery of an HIV integrase inhibitor with an excellent resistance profile

D. J. Bull, R. A. Bissell, S. Butler, 2013 .

Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti-Tissue Factor Pathway Inhibitor Antibody, PF-06741086.

John E. Murphy, C. Parng, M. Peraza, 2018, Journal of pharmaceutical sciences.

Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

Bill J Smith, T. Maurer, K. Beaumont, 2009, Journal of clinical pharmacology.

PEGylation of somatropin (recombinant human growth hormone): Impact on its clearance in humans

R. Xie, R. Webster, A. Edgington, 2008, Xenobiotica; the fate of foreign compounds in biological systems.

A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs

Jeffrey R. Chabot, J. Narula, H. Neubert, 2021, Frontiers in Bioinformatics.

Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations

D. Walker, I. Gardner, J. Davis, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetics and metabolism of UK-383,367 in rats and dogs: A rationale for long-lived plasma radioactivity

S. Roffey, A. Nedderman, G. Allan, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Medicinal chemistry approaches to avoid aldehyde oxidase metabolism.

I. Gardner, S. Bagal, K. Omoto, 2012, Bioorganic & medicinal chemistry letters.

Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies.

L. Lian, N. Kitteringham, B. K. Park, 2012, Molecular pharmaceutics.

The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF‐4878691)

M. Fidock, C. Laxton, M. Perros, 2011, Clinical pharmacology and therapeutics.

The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile—Part 2

Stephen M. Shaw, J. Chiva, Florian Wakenhut, 2014, ChemMedChem.

The discovery of adamantyl-derived, inhaled, long acting beta(2)-adrenoreceptor agonists.

Mark E Bunnage, M. Bunnage, David A. Price, 2008, Bioorganic & medicinal chemistry letters.

Pyrazole NNRTIs 1: design and initial optimisation of a novel template.

A. Wood, R. Corbau, C. Mowbray, 2009, Bioorganic & medicinal chemistry letters.

Optimization of 5‐Aryloxyimidazole Non‐Nucleoside Reverse Transcriptase Inhibitors

R. Corbau, D. Hay, C. Mowbray, 2008, ChemMedChem.

Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels

Alex Phipps, Hannah M Jones, Tanya L Hay, 2016, Clinical Pharmacokinetics.

A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data

P. Jasper, H. Barton, H. Neubert, 2019, CPT: pharmacometrics & systems pharmacology.

Microbial oxidative metabolism of diclofenac: production of 4′-hydroxydiclofenac using Epiccocum nigrum IMI354292

S. Jezequel, R. Webster, T. Winchester, 1998, Applied Microbiology and Biotechnology.

The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.

Mark E Bunnage, M. Bunnage, David A. Price, 2007, Bioorganic & medicinal chemistry letters.

The Synthesis of the Glucuronide Metabolite of UK-157,147 Using Immobilised Uridine 5′-Diphosphoglucuronyl Transferase and Traditional Organic Chemistry Techniques (Imidate Method)

K. Beaumont, R. Webster, M. Ritzau, 2001 .

THE SYNTHESIS OF THE GLUCURONIDE USING IMMOBILISED URIDINE TRANSFERASE AND TRADITIONAL ORGANIC CHEMISTRY TECHNIQUES (IMIDATE METHOD) METABOLITE OF UK-157,147 5'-DIPHOSPHOGLUCURONYL

K. Beaumont, R. Webster, M. Ritzau, 2001 .

I. Gardner, I Gardner, T. Jenkins, 2008, Xenobiotica; the fate of foreign compounds in biological systems.

Analytical methodologies for determining the metabolism and disposition of PEGylated biopharmaceuticals

L. Lian, N. Kitteringham, B. K. Park, 2011 .

Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.

Julian Blagg, P. Fish, R. Butt, 2007, Journal of medicinal chemistry.

PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans.

D. Walker, R. Xie, R. Webster, 2008, Xenobiotica; the fate of foreign compounds in biological systems.

Pyrazole NNRTIs 3: optimisation of physicochemical properties.

A. Wood, R. Corbau, C. Mowbray, 2009, Bioorganic & medicinal chemistry letters.

Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXaI16L in Preclinical Species

C. Parng, B. Gorovits, R. Webster, 2019, The AAPS Journal.